Maximilian Reichert

10PUBLICATIONS
70CO-AUTHORS
Molecular targetsInnate immunityCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jun 15, 2026
Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis.

|Jun 01, 2026
Autophagy supports the storage of lytic granules in human NK cells.

|Jan 08, 2026
TIGIT disruption rescues the antitumor activity of low avidity TCR-engineered T cells by increasing TCR signal strength.

Martina Spiga, Alessia Potenza, Zulma Magnani

|May 12, 2025
Activation of RAS/MEK/ERK signalling drives biliary differentiation in primary liver cancer.

Thomas Rösner, Carina Rupp, Christian Lechler

|Mar 11, 2025
The Biology in the Pattern: Metastatic Organotropism and Clinical Outcome Depend on DNA Damage Response and Immune Interactions in Pancreatic Cancer.

Aristeidis Papargyriou, Maximilian Reichert

|Jan 21, 2025
Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response.

Stefanie Höfer, Larissa Frasch, Sarah Brajkovic

Pageof 2

Frequent Collaborators

4 joint publications

Dieter Saur

3 joint publications

Aristeidis Papargyriou

3 joint publications

Günter Schneider

2 joint publications

Katja Steiger